genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2016
Aveo Oncology
Industry News
AVEO Agrees to $4M Penalty to Settle SEC Fraud Charges
Cancer
AVEO Oncology Awards European Rights to Tivozanib for Up to $396.5M+
Cancer
Aveo Inks Exclusive Antibody Deal with Novartis
Cancer
With New Partner, Aveo Revives Tivozanib Development
Cancer
Aveo to Co-Develop NSCLC Candidate with Biodesix’ VeriStrat
Cancer
Biogen Idec Gives Worldwide AV-203 Rights Back to Aveo
News
Aveo’s “Sad Day”: 62% of Workforce Lose Jobs
Cancer
Aveo Cuts Workforce, Research Spending
Cancer
Aveo, Astellas Report Positive Data from Phase III Comparative Tivozanib Trial in RCC
Scroll Up
Scroll Up
